GLSI Skyrockets on Cancer Trial Results

[RagingBull Elite]( Dear trader— Jeff Bishop here, It’s easy to forget that other stocks in the healthcare industry are set to pop off, when I look to the headlines and see they’re focused on “vaccine plays” like PFE and MRNA. The latest news tells us that the FDA deems the Pfizer-BioNTech vaccine safe and effective and that it can get the green light within days. The UK already administered its first official dose on Tuesday. For the U.S., there’s an advisory committee meeting for the Pfizer-BioNTech vaccine today, and this is a major turning point for the fight against the pandemic. Now, PFE and MRNA both closed lower yesterday, which makes sense to me given the amount of risk there is on the table for these names. A much smaller biotech company took the spotlight on Wednesday. With a market cap of just 686.28M, Greenwich Lifesciences (GLSI) skyrocketed over 2,000% yesterday afternoon, thanks to upbeat results from its cancer trail. In All-Access today, we’ll recap the huge move, and share a few related stocks with the potential to ride the tailwinds of its action. GLSI was one of the craziest movers of the year. Just two days ago, shares of Greenwich LifeSciences closed at around $5. Yesterday the stock reached as high as $158.07 at one point, a nearly 3,000% gain. While GLSI ended up pulling back before the market close, it still finished up 998.35%. Of course, I’m not saying you could’ve made those gains, I just want to review the move the stock had and what caused it… because understanding these plays are beneficial for the future, in my opinion. So, what happened there? Before the open, the company announced impressive phase 2b trial data for its breast cancer drug GP2: there were 0 cases of breast cancer recurrence among patients who took the drug over a median period of 5 years after a surgery. According to Greenwich LifeSciences CEO Snehal Patel, GP2 could reach a potential market worth $5 billion and the company is now preparing to enter into Phase 3 of the clinical trial in 2021. And here is what happened with the stock, and how one may have traded it. GLSI yesterday most likely was in the “avoid” category for most traders. The stock was halted multiple times and the moves just seemed too risky. Especially with such a fast-moving stock, the chances of getting the same entries and exits as another trader is slim to none, in my opinion. And rightfully so: it’s just not that easy to buy a stock that is up multiple hundred percent on the day. However, the best traders out there thrive on opportunities like these. There were three trade ideas that stood out in GLSI: 1) Long high of day break 2) Parabolic short 3) Bounce long While each of those trades are worth their own review, I think the bounce trade is a good strategy to learn: you see, with that, traders can define their risk, and wouldn’t have to pay for expensive stock locates as one would for a short trade. Here are some of the variables to take away from GLSI to learn how to get better at bounce trades: - Low float or high short interest — 996k shares - Triple-digit gains on the day or more — 2,941% - Panic selling: the lower and faster, the better — from $158 to $45 in two minute bars, down around 70% To learn these plays, I think one can start by finding oversold setups and figuring out what makes one better than the other. Of course, it’s always important to be comfortable with taking the risk and wise to talk to a financial advisor or broker before taking on new strategies. Moves like GLSI typically don’t happen often… I think the market is generally efficient at pricing in likelihoods of trial outcomes and it is quite rare that traders and investors are caught so seriously off guard. I won’t even try to say I called or could’ve called this one— I think these kinds of trades on trials are pure “gambling” by nature because to me, it’s a coin-toss event. The good news for us, though, is that surprising moves can bring in a multitude of sympathy plays— e.g. stocks with similar storylines and potential. Think about the sector runs I talk about so often— it typically starts with one name that goes on to fuel many others. A move as large as GLSI, and an announcement so significant may send traders scanning for other biotechs with similar research and technologies. Neither us, nor anybody else, is sure if breast cancer is cured but one thing is certain— even a distant possibility can be enough to trigger a buying spree in related names. Here’re some of the stocks I think traders will be watching, shall GLSI keep at it: Xenetic Biosciences (XBIO): Immutep (IMMP): Geovax Labs (GOVX): [How I’m Trading DoorDash And Airbnb’s IPOs]( By Ben Sturgill of Daily Profit Machine [3D Printing Set To Heat Up?]( By Jason Bond of Jason Bond Picks [Small Caps – Big Gains]( By JC Parets of Chart Hunter [The Catalyst Runup Explained]( By Kyle Dennis of Biotech Breakouts RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from support@ragingbull.com]( [Unsubscribe from all RagingBull emails]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Profit Prism you will need to contact us [here]( if you want to cancel your subscription. Opting out of emails does not remove you from your service at PetraPicks.com.